Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo

Rastogi, Namrata, Baker, Sarah ORCID: https://orcid.org/0000-0002-7474-9757, Man, Stephen ORCID: https://orcid.org/0000-0001-9103-1686, Uger, Robert A., Wong, Mark, Coles, Steve J., Hodges, Marie, Gilkes, Amanda, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Darley, Richard ORCID: https://orcid.org/0000-0003-0879-0724 and Tonks, Alex ORCID: https://orcid.org/0000-0002-6073-4976 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1) , pp. 155-159. 10.1111/bjh.17125

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (519kB) | Preview

Abstract

Treatment of relapsed/resistant acute myeloid leukaemia (AML) remains a significant area of unmet patient need, the outlook for most patients remaining extremely poor. A promising approach is to augment the anti‐tumour immune response in these patients; most cancers do not activate immune effector cells because they express immunosuppressive ligands. We have previously shown that CD200 (an immunosuppressive ligand) is overexpressed in AML and confers an inferior overall survival compared to CD200low/neg patients. Here we show that a fully human anti‐CD200 antibody (TTI‐CD200) can block the interaction of CD200 with its receptor and restore AML immune responses in vitro and in vivo.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine European Cancer Stem Cell Research Institute (ECSCRI)
Publisher:	Wiley
ISSN:	0007-1048
Funders:	Bloodwise, MRC
Date of First Compliant Deposit:	10 September 2020
Date of Acceptance:	4 September 2020
Last Modified:	06 Nov 2024 22:46
URI:	https://orca.cardiff.ac.uk/id/eprint/134761

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item